Avanos Medical Expects FY23 Revenue Between $675M-$685M Vs. 680.63M Estimate, Expects FY23 Adjusted EPS Of $1.05-$1.15 Vs. 1.09 Estimate (Prior Outlook: $1.05-$1.15)
Portfolio Pulse from Benzinga Newsdesk
Avanos Medical has provided its FY23 revenue guidance, expecting it to be between $675M-$685M, which is in line with the $680.63M estimate. The company also expects its FY23 adjusted EPS to be between $1.05-$1.15, which is also in line with the $1.09 estimate. The outlook remains unchanged from the prior forecast.
November 01, 2023 | 11:21 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Avanos Medical's FY23 revenue and EPS guidance is in line with estimates, indicating stable financial performance. The unchanged outlook suggests the company's confidence in its projections.
Avanos Medical's FY23 revenue and EPS guidance aligns with market estimates, indicating that the company's financial performance is expected to be stable. The unchanged outlook from the prior forecast suggests that the company is confident in its projections, which could be perceived positively by investors. However, as the guidance is in line with estimates, it is unlikely to cause significant movement in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100